Industry

USFDA gives approval for Glycopyrrolate Injection USP

The approval for Glycopyrrolate clears the path for more internally manufactured injectable products,” said Vinita Gupta, CEO, Lupin.

The Health Master

February 9, 2023

135

Last Updated on October 10, 2024 by The Health Master

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated New Drug Application for Glycopyrrolate Injection USP, a generic equivalent of Robinul Injection, 0.2 mg/mL of Hikma Pharmaceuticals.

The product marks the first approval from Lupin’s new injectable facility in Nagpur, India.

“We are committed to building a strong injectable business as part of our growth strategy. With the approval of our Nagpur facility, we can now fast-track our injectable portfolio rollout and build upon our R&D capabilities for complex products.

Click for more articles on USFDA

The approval for Glycopyrrolate clears the path for more internally manufactured injectable products,” said Vinita Gupta, CEO, Lupin.

Glycopyrrolate Injection USP, 0.2 mg/mL and 0.4 mg/2 mL (0.2 mg/mL) single-dose vials, and 1 mg/5 mL (0.2 mg/mL) and 4 mg/20 mL (0.2 mg/mL) multiple-dose vials (RLD Robinul) had estimated annual sales of $39 million in the US (IQVIA MAT December 2022).

Other drugs approval by USFDA

USFDA gives approval for Diclofenac Sodium Topical Solution USP

USFDA approves this anemia drug for patients on dialysis

USFDA gives nod for Technetium Mertiatide Injection

USFDA tentative nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets

USFDA approves this drug for rare blood cancer

USFDA gives approval for Amphetamine capsules

Also read

PCI issues notification on Exit Examination for D.Pharm course

Updated list of Medical Device Testing Laboratories (MDTLs)

Methotrexate may increased risk of skin cancer: Study

Takeda Pharma seeks DCGI permission for Dengue Vaccine trial